Jennelle C Hodge1, Kathryn E Pearce2, Amy C Clayton2, Florin A Taran3, Elizabeth A Stewart4. 1. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA. Electronic address: jennelle.hodge@csmc.edu. 2. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN. 3. Department of Obstetrics and Gynecology and Surgery, Mayo Clinic, Rochester, MN; Department of Obstetrics and Gynecology, University Women's Clinic, Tübingen, Germany. 4. Department of Obstetrics and Gynecology and Surgery, Mayo Clinic, Rochester, MN.
Abstract
OBJECTIVE: This study aimed to determine whether 1p deletion defines a subset of cellular leiomyomata (CL), which is a hypercellular variant of uterine leiomyomata that may have delayed malignant potential, and to correlate this genetic change with clinical and pathologic characteristics including those present in uterine sarcomas. STUDY DESIGN: Available CL cases at the Mayo Clinic (n = 101) and variant cases reported in another article (n = 16) were identified. Each case with sufficient tissue that met histologic criteria for CL when reviewed by a single pathologist underwent interphase fluorescence in situ hybridization to determine the presence of 1p deletion. Clinical characteristics of women with confirmed CL were compared on the basis of 1p deletion status using univariate analysis. RESULTS: Of the Mayo Clinic cohort of histologically confirmed CL, 23% had deletion of 1p. Women with this subset of CL, when compared to those without 1p deletion, were more likely to be postmenopausal (P = .049) and their uteri tended to be heavier (P = .039) with a larger dominant leiomyoma (P = .030). The pathologic features associated with 1p deletion were high cellularity (P = .036) and hyaline necrosis (P = .047), which remained significant after inclusion of the CL cases from a previously published series. CONCLUSION: Deletion of 1p occurs in approximately one-quarter of CL cases. This genetic alteration is potentially associated with clinicopathologic features that are present in uterine sarcomas, which suggests a distinct clinical entity that may have malignant potential. Our findings are particularly pertinent considering the increased preference for uterine-sparing options in leiomyoma treatment, suggesting assessment of 1p deletion status in CL may influence clinical surveillance decisions.
OBJECTIVE: This study aimed to determine whether 1p deletion defines a subset of cellular leiomyomata (CL), which is a hypercellular variant of uterine leiomyomata that may have delayed malignant potential, and to correlate this genetic change with clinical and pathologic characteristics including those present in uterine sarcomas. STUDY DESIGN: Available CL cases at the Mayo Clinic (n = 101) and variant cases reported in another article (n = 16) were identified. Each case with sufficient tissue that met histologic criteria for CL when reviewed by a single pathologist underwent interphase fluorescence in situ hybridization to determine the presence of 1p deletion. Clinical characteristics of women with confirmed CL were compared on the basis of 1p deletion status using univariate analysis. RESULTS: Of the Mayo Clinic cohort of histologically confirmed CL, 23% had deletion of 1p. Women with this subset of CL, when compared to those without 1p deletion, were more likely to be postmenopausal (P = .049) and their uteri tended to be heavier (P = .039) with a larger dominant leiomyoma (P = .030). The pathologic features associated with 1p deletion were high cellularity (P = .036) and hyaline necrosis (P = .047), which remained significant after inclusion of the CL cases from a previously published series. CONCLUSION: Deletion of 1p occurs in approximately one-quarter of CL cases. This genetic alteration is potentially associated with clinicopathologic features that are present in uterine sarcomas, which suggests a distinct clinical entity that may have malignant potential. Our findings are particularly pertinent considering the increased preference for uterine-sparing options in leiomyoma treatment, suggesting assessment of 1p deletion status in CL may influence clinical surveillance decisions.
Authors: Min Ju Park; Hailian Shen; Nam Hee Kim; Fangjian Gao; Courtney Failor; Jennifer F Knudtson; Jessica McLaughlin; Sunil K Halder; Tuomas A Heikkinen; Pia Vahteristo; Ayman Al-Hendy; Robert S Schenken; Thomas G Boyer Journal: J Clin Endocrinol Metab Date: 2018-11-01 Impact factor: 5.958
Authors: Miika Mehine; Eevi Kaasinen; Hanna-Riikka Heinonen; Netta Mäkinen; Kati Kämpjärvi; Nanna Sarvilinna; Mervi Aavikko; Anna Vähärautio; Annukka Pasanen; Ralf Bützow; Oskari Heikinheimo; Jari Sjöberg; Esa Pitkänen; Pia Vahteristo; Lauri A Aaltonen Journal: Proc Natl Acad Sci U S A Date: 2016-01-19 Impact factor: 11.205
Authors: Qiwei Yang; Michal Ciebiera; Maria Victoria Bariani; Mohamed Ali; Hoda Elkafas; Thomas G Boyer; Ayman Al-Hendy Journal: Endocr Rev Date: 2022-07-13 Impact factor: 25.261
Authors: Eucharist H S Kun; Yvonne T M Tsang; Sophia Lin; Sophia Pan; Tejas Medapalli; Anais Malpica; JoAnne S Richards; David M Gershenson; Kwong-Kwok Wong Journal: Sci Rep Date: 2020-11-26 Impact factor: 4.379
Authors: Alla S Koltsova; Olga A Efimova; Olga V Malysheva; Natalia S Osinovskaya; Thomas Liehr; Ahmed Al-Rikabi; Natalia Yu Shved; Iskender Yu Sultanov; Olga G Chiryaeva; Maria I Yarmolinskaya; Nikolai I Polenov; Vladislava V Kunitsa; Maka I Kakhiani; Tatyana G Tral; Gulrukhsor Kh Tolibova; Olesya N Bespalova; Igor Yu Kogan; Andrey S Glotov; Vladislav S Baranov; Anna A Pendina Journal: Biomedicines Date: 2021-11-26